NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis $1.91 +0.01 (+0.53%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.90 -0.01 (-0.79%) As of 06/5/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LXRX alerts:Sign Up Key Stats Today's Range$1.87▼$1.9450-Day Range$1.51▼$2.4452-Week Range$0.64▼$2.53Volume1.76 million shsAverage Volume3.10 million shsMarket Capitalization$848.41 millionP/E RatioN/ADividend YieldN/APrice Target$4.55Consensus RatingHold Company Overview Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases. The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy. In addition to this marketed asset, Lexicon maintains a diversified pipeline with programs spanning metabolic diseases, neuropathic pain, and rare genetic disorders. Key development candidates include small-molecule inhibitors modulating glucose transport and neuroreceptor activity, each designed to address unmet medical needs through precise mechanism-based intervention. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals has been publicly traded on the NASDAQ exchange since 2000. The company collaborates with academic institutions, strategic partners and patient advocacy groups to advance its research and expand clinical development globally. With a core scientific team experienced in genomics, medicinal chemistry and clinical development, Lexicon continues to pursue innovative solutions aimed at improving patient outcomes across a variety of therapeutic areas.AI Generated. May Contain Errors. Read More Lexicon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreLXRX MarketRank™: Lexicon Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 698th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLexicon Pharmaceuticals has a consensus price target of $4.55, representing about 138.2% upside from its current price of $1.91.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Lexicon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to decrease in the coming year, from ($0.17) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -27.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -27.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 6.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexicon Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.84% of the float of Lexicon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.22.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently increased by 9.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest12 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.00% of the stock of Lexicon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexicon Pharmaceuticals' insider trading history. Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXRX Stock News HeadlinesHow The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst UpdatesJune 4 at 3:15 PM | finance.yahoo.comLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsJune 3 at 8:00 AM | globenewswire.comTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.June 6 at 1:00 AM | Porter & Company (Ad)Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comSA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRXMay 27, 2026 | msn.comLexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade)May 26, 2026 | seekingalpha.comCiti Raises its Price Target on Lexicon Pharmaceuticals (LXRX)May 22, 2026 | insidermonkey.comLexicon Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:LXRXMay 21, 2026 | benzinga.comSee More Headlines LXRX Stock Analysis - Frequently Asked Questions How have LXRX shares performed this year? Lexicon Pharmaceuticals' stock was trading at $1.15 at the beginning of the year. Since then, LXRX shares have increased by 66.1% and is now trading at $1.91. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported $0.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.04. The biopharmaceutical company had revenue of $21.10 million for the quarter, compared to analysts' expectations of $9.79 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 18.64% and a negative net margin of 37.46%. Read the conference call transcript. Who are Lexicon Pharmaceuticals' major shareholders? Lexicon Pharmaceuticals' top institutional investors include Siren L.L.C. (9.97%), Renaissance Technologies LLC (0.36%), ADAR1 Capital Management LLC (0.17%) and Bank of America Corp DE (0.12%). Insiders that own company stock include Raymond Debbane, Invus Global Management, Llc, Lonnel Coats, Jeffrey L Wade and Wendy Mcdermott. View institutional ownership trends. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA). Company Calendar Last Earnings5/07/2026Today6/06/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 LXRX's financial health is in the Green zone, according to TradeSmith. LXRX has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees140Year Founded1995Price Target and Rating Average Price Target for Lexicon Pharmaceuticals$4.55 High Price Target$6.00 Low Price Target$3.10 Potential Upside/Downside+138.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.34 million Net Margins-37.46% Pretax Margin-37.46% Return on Equity-18.64% Return on Assets-11.79% Debt Debt-to-Equity Ratio0.24 Current Ratio18.80 Quick Ratio18.77 Sales & Book Value Annual Sales$69.64 million Price / Sales12.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book6.37Miscellaneous Outstanding Shares444,196,000Free Float382,009,000Market Cap$848.41 million OptionableOptionable Beta1.07 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:LXRX) was last updated on 6/6/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...Stansberry Research | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredHow to get into the SpaceX IPO before June 12Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredIn 30 days, you'll wish you'd read this emailA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredAre you missing out on reliable earnings season gains?Danielle Shay doesn't wait for earnings season - she trades pre-earnings setups year-round using her Five Star...Simpler Trading | SponsoredWhy is this free?Simple Options Trading For Beginners normally sells for $29.97 - but right now Bill Poulos has opened a free w...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
